home · filing · 0001140361-22-009916
8-K
filed March 17, 2022, 7:59 PM ET
ticker BMY
CIK 0000014272
leadership
confidence high
sentiment neutral
materiality 0.40
Bristol-Myers appoints Sharon Greenlees as new SVP and Controller
BRISTOL MYERS SQUIBB CO
Sharon Greenlees becomes Senior VP and Controller effective April 25, 2022; most recently at AbbVie as VP and Controller, R&D Finance.
Karen Murphy Santiago, current SVP and Controller, will depart by May 1, 2022.
Greenlees has a B.S. in Accounting and is a CPA.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2022-04-25
Filed March 17, 2022, 7:59 PM ET
Effective April 25, 2022, Ms. Sharon Greenlees will be appointed Senior Vice President and Controller of Bristol-Myers Squibb Company (the “Company”).
Effective 2022-05-01
Successor Sharon Greenlees
Filed March 17, 2022, 7:59 PM ET
Ms. Karen Murphy Santiago, Senior Vice President and Controller, will leave the Company by May 1, 2022.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Sharon Greenlees was appointed as Senior Vice President and Controller at BRISTOL MYERS SQUIBB CO.
Action appointed
Role Senior Vice President and Controller
Exact text from the filing
Effective April 25, 2022, Ms. Sharon Greenlees will be appointed Senior Vice President and Controller of Bristol-Myers Squibb Company (the “Company”).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Karen Murphy Santiago departed as Senior Vice President and Controller at BRISTOL MYERS SQUIBB CO.
Action leave
Role Senior Vice President and Controller
Exact text from the filing
Ms. Karen Murphy Santiago, Senior Vice President and Controller, will leave the Company by May 1, 2022.
View on SEC.gov
Source: SEC EDGAR
accession 0001140361-22-009916
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.